Micafungin, a new Echinocandin: Pediatric Development
|
|
- Maude Small
- 6 years ago
- Views:
Transcription
1 Micafungin, a new Echinocandin: Pediatric Development Andreas H. Groll, M.D. Infectious Disease Research Program Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology University Children s Hospital Muenster
2 Micafungin: Pediatric Indications and Dosages Indication Body weight > 4 kg Dose Body weight 4 kg Treatment of invasive candidiasis Prophylaxis of Candida infection 1 mg/day* 2 mg/kg/day* 5 mg/day 1 mg/kg/day * If the patient s response is inadequate, e.g. persistence of cultures or if clinical condition does not improve, the dose may be increased to 2 mg/day in patients weighing > 4 kg or 4 mg/kg/day in patients weighing 4 kg MYCAMINE (micafungin sodium) for injection SmPC. Astellas Pharma Europe Ltd., September 28
3 Micafungin Pediatric Program Pediatric PK Study in Adolescents or Older Children 2-17 Years Old (n = 77) Dose selection P III Candida (n = 52) P III Prophylaxis (n = 39) P II Candida (n = 53) P II Aspergillus (n = 7) Pediatric PK Studies in Premature Neonates ( 4 weeks, 5g) (n = 23)
4 Clinical Efficacy
5 Pediatric Phase III Substudy: MICA vs. L-AMB for Invasive Candidiasis Double-blind, multicenter comparative study evaluating micafungin vs. AMBISOME in pts with inv. candidiasis subpopulation of pediatric patients <15 years Candidemia or invasive candidiasis primary endpoint: Clinical + mycological EOT 1:1 stratified randomization MICA 2mg/kg/d vs. LAMB (3 mg/kg/d) for minimum of 14 days Full analysis set (all randomized patients) Per protocol set ( 5 doses of study drug) Queiroz-Telles et al. PIDJ 8
6 Pediatric Substudy MICA vs. L-AMB: Baseline Characteristics Parameter FAS, n (%) PPS, n (%) MICA (n = 52) L-AmB (n = 54) MICA (n = 41) L-AmB (n = 42) Age in years, mean (range) 4. (<1 15) 2.2 (<1 15) 3.1 (<1 14) 2. (<1 15) Neutropenic 7 (13.5) 13 (24.1) 5 (12.2) 1 (23.8) Hospitalized in ICU 3 (57.7) 22 (4.7) 24 (58.5) 16 (38.1) Underlying disorder* # Haematological malignancy Prematurity at birth Gastrointestinal disorder Risk category* Intravenous line/device Antibiotic use Corticosteroid therapy Other immunosuppressive Total parenteral nutrition Other 15 (28.8) 1 (19.2) 1 (19.2) 19 (36.5) 14 (26.9) 13 (25.) 11 (21.2) 7 (13.5) 12 (23.1) 12 (22.2) 11 (2.4) 8 (14.8) 13 (24.1) 12 (22.2) 7 (13.) 12 (22.2) 4 (7.4) 8 (14.8) 8 (19.5) 9 (22.) 9 (22.) 17 (41.5) 13 (31.7) 11 (26.8) 7 (17.1) 7 (17.1) 11 (26.8) 1 (23.8) 7 (16.7) 7 (17.7) 11 (26.2) 1 (23.8) 6 (14.3) 9 (21.4) 4 (9.5) 6 (14.3) *Patients could be included in more than one category # Only top 3 underlying disorders are shown Queiroz-Telles et al. PIDJ 8
7 Pediatric Substudy MICA vs. L-AMB: Site and Species MICA (n = 52) FAS, n (%) PPS, n (%) L-AmB (n = 54) MICA (n = 41) L-AmB (n = 42) Candidemia 47 (9.4) 51 (94.4) 38 (92.7) 4 (95.2) Invasive candidiasis 5 (9.6) 3 (5.6) 3 (7.3) 2 (4.8) Infecting species* Candida albicans Non-albicans Candida C. parapsilosis C. tropicalis C. krusei C. guilliermondii C. lipolytica Other non-albicans Candida 19 (36.5) 31 (59.6) 12 (23.1) 1 (19.2) 4 (7.7) 3 (5.8) 2 (3.8) 3 (5.8) 15 (27.8) 38 (7.4) 17 (31.5) 13 (24.1) 1 (1.9) 2 (3.7) 5 (9.3) 16 (39.) 25 (61.) 11 (26.8) 7 (17.1) 3 (7.3) 2 (4.9) 1 (2.4) 2 (4.9) 14 (33.3) 8 (19.) 14 (33.3) 8 (19.) 1 (2.4) 2 (4.8) 3 (7.1) *Patients could have an infection caused by more than one Candida species Including C. pelliculosa, C. utilis, C. rugosa, C. keyfr and C. glabrata Queiroz-Telles et al. PIDJ 8
8 Pediatric Substudy MICA vs. L-AMB: Treatment Success Treatment success rate MICA 7 13 L-AmB Overall Neutropenic Overall Neutropenic patients patients Full analysis set Per-protocol set Queiroz-Telles et al. PIDJ 8
9 Pediatric Substudy MICA vs. L-AMB: Success by Species 1 15 MICA L-AmB Any Candida spp. C. albicans Non-albicans Candida C. parapsilosis C. tropicalis C. krusei C. guilliermondii Other Queiroz-Telles et al. PIDJ 8 Treatment success rate (%)
10 Pediatric Substudy MICA vs. L-AMB: Success by Infection Site Treatment success rate (%) MICA L-AmB MICA L-AmB FAS PPS Queiroz-Telles et al. PIDJ 8
11 Pediatric Subset, Phase III trial Micafungin vs. Fluconazole Randomisation (1:1) Micafungin 5 mg/day (1 mg/kg/day for patients weighing < 5 kg) Fluconazole 4 mg/day (8 mg/kg/day for patients weighing < 5 kg) Treatment continued until one of the following, whichever occurred first: 5 days after engraftment (defined as an absolute neutrophil count of 5 cells/μl after the nadir absolute count) treatment day 42 after HSCT development of proven, probable or suspected invasive fungal infection development of unacceptable drug toxicity death withdrawal from study participation (patient s decision) discontinuation of study treatment (investigator s decision) van Burik JA et al. CID 24; 39:147 16
12 Pediatric subset, MICA vs. FLU: Treatment success 8 Treatment success rate (%) n = Micafungin Fluconazole Modified intent-to-treat (mitt) population van Burik JA et al. CID 24; 39:147 16
13 Micafungin: Phase II, Systemic Candidiasis Pediatric patients ( 15 years) with confirmed SCI de novo: newly diagnosed, with 48 hours prior systemic antifungal therapy Efficacy failure: >5 days prior systemic antifungal therapy with no response MICA alone (n=16) MICA alone (n=8) MICA in combination with existing antifungal therapy at study entry (n=31) MICA dose was 5 mg/day (1 mg/kg/day if weight 4 kg) or 1 mg/day (2 mg/kg/day) in pts with germ-tube negative infection / non-albicans Candida Option to dose-escalate in 1 mg/kg increments Arrieta, ECCMID 7
14 Micafungin: Phase II, Systemic Candidiasis Treatment success (%) All Age group (years) Arrieta, ECCMID 7
15 Micafungin: Phase II, Invasive Aspergillosis Multinational, non-comparative study of MICA alone or in combination in pediatric pts. with proven/probable IA EORTC/MSG criteria; independent DRC Initial dose: 1.5mg/kg; dose escalation permitted 58 patients; 9 ±4.3 years (3mo-16y) 54 refractory, 4 newly diagnosed 56 pts. combination therapy, 2 MICA alone Mean of 2.±1.2 mg/kg/d for median of 67±85 days Flynn, ICAAC 6
16 Micafungin: Phase II, Invasive Aspergillosis Overall response rate: 26/58 (45%) Complete response, 9 (16%) Partial response, 17 (29%) Stable disease, 6 (1%) Pulmonary IA, 2/49 (41%), dissem. IA 4/6 (67%) 13/58 (22%) discontinued prematurely, mostly due progression of underlying disease or IA Flynn ICAAC 6
17 Micafungin in Pediatric Patients: Efficacy in Clinical Trials Therapeutic Category Phase III Invasive candidiasis or candidemia Prophylaxis of fungal infections Phase II Invasive aspergillosis Invasive candidiasis or candidemia Phase I PK, safety, and tolerability *Either alone or in combination. Treatment Micafungin 52 24/3 (8.) Liposomal Amphotericin B N 54 31/4 (77.5) Micafungin 39 6/7 (85.7) Treatment Response, n/n (%) by Age Group (years) to 2 3 to 7 8 to to <16 Overall 5/7 (71.4) 6/9 (66.7) Fluconazole 45 6/13 (46.2) 4/7 (57.1) Micafungin* 58 2/5 (4.) Micafungin 53 19/28 (67.9) 7/11 (63.6) Micafungin 69 4/5 (8.) 3/8 (37.5) 1/3 (33.3) 4/7 (57.1) 2/2 (1) 1/14 (71.4) 7/12 (58.3) 4/6 (66.7) 1/19 (52.6) 4/6 (66.7) 36/52 (69.2) 4/54 (74.1) 27/39 (69.2) 24/45 (53.3) 7/16 (43.8) 5/18 (27.8) 12/19 (63.2) 26/58 (44.8) 8/9 (88.9) 4/5 (8.) 38/53 (71.7) 23/3 (76.7) 13/22 (59.1) 9/12 (75.) 49/69 (71.) Arrieta et al. 29
18 Clinical Safety
19 Pediatric Substudy MICA vs. L-AMB: Treatment related AEs (n = 19) 42.6 (n = 23) MICA (n = 52) L-AmB (n = 54) Patients, % (n = 2) 9.3 (n = 5) Overall AEs Serious AEs Queiroz-Telles et al. PIDJ 8
20 Pediatric Substudy MICA vs. L-AMB: Treatment-related AEs MICA (n = 52) L-AmB (n = 54) Overall 19 (36.5%) 23 (42.6%) Serious 2 (3.8%) 5 (9.3%) Common AEs (>5% in either group) Fever Vomiting LFT abnormal Thrombocythemia Hypokalemia AEs leading to treatment discontinuation 2 (3.8%) 1 (1.9%) 1 (1.9%) 3 (5.8%) 6 (11.1%) 4 (7.4%) 3 (5.6%) 3 (5.6%) 6 (11.1%) Any Kidney failure Bilirubinemia Liver damage Sepsis 1 (1.9%) 1 (1.9%) 3 (5.6%) 1 (1.9%) 1 (1.9%) 1 (1.9%) Queiroz-Telles et al. PIDJ 8
21 Overall Safety in Clinical Trials (n=296) Incidence of AEs All causality (>2%) At least possibly related* to micafungin (>2%) At least possibly related* to micafungin and leading to treatment discontinuation (7 patients - < 2.5%) vomiting (31.8%), pyrexia (22.3%), diarrhea (21.6%), nausea (21.3%), hypokalemia (2.9%) hypokalemia (3.%), ALT increased (3.%), hyperbilirubinemia (2.%), AST increased (2.%), LFT abnormal (2.%), AP increased (2.%), hypertension (2.%) neutropenia, AST/ALT increased, rash, (3 patients with underlying leukemia); jaw and joint pain, hyperbilirubinemia, creatinine increased (3 patients with underlying HSCT); creatinine increased (1 patient with premature birth). *Investigator-assessed causal relationship Arrieta et al. 29
22 Hepatic tolerability in clincal trials (n=296) Normal at baseline to > ULN at EOT Normal at baseline to 2.5 x ULN at EOT High at baseline to normal at EOT 5 Patients (%) n = AST ALT ALT: alanine aminotransferase; AST: aspartate aminotransferase; EOT: end of treatment ULN: upper limit of normal; normal: ULN; high > ULN Increase is measured as ULN at EOT Arrieta A et al. 47th ICAAC (27)
23 Conclusions
24 Conclusions Micafungin has demonstrated efficacy in pediatric patients with SCIs Micafungin as effective as L-AmB in both neutropenic and non-neutropenic patients Micafungin effective against both C. albicans and non-albicans Candida species Micafungin effective as prophylaxis against IFIs in children undergoing HSCT Well tolerated in clinical trials across all age groups with low (<2.5%) AE-related discontinuation rates
Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013
Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version 1.0 5 February 2013 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised
More informationAmphotericin B Lipid Complex (Abelcet ) 05/06
Amphotericin B Lipid Complex (Abelcet ) Structure and Activity AMB : DMPC : DMPG lipid complex, 10:7:3 mol:mol ribbon-like lipid structures, 1.6-11 µm in diameter binds to ergosterol disturbance of cell
More informationanidulafungin 100mg powder and solvent for concentrate for solution for infusion (Ecalta ) No. (465/08) Pfizer Ltd
Scottish Medicines Consortium Re-Submission anidulafungin 100mg powder and solvent for concentrate for solution for infusion (Ecalta ) No. (465/08) Pfizer Ltd 10 October 2008 The Scottish Medicines Consortium
More informationCurrent options of antifungal therapy in invasive candidiasis
Current options of antifungal therapy in invasive candidiasis Saloua Ladeb Bone Marrow Transplant Center Tunis HAMMAMET 24 th April 2012 DEFINITION One or more positive results on blood culture for Candida
More informationAntifungals in Invasive Fungal Infections: Antifungals in neutropenic patients
BVIKM-SBIMC La Hulpe, 6 November 2008 Antifungals in Invasive Fungal Infections: Antifungals in neutropenic patients Johan Maertens, MD Acute Leukemia and SCT Unit University Hospital Gasthuisberg Catholic
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationMANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS
MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine Numbers of Cases of Sepsis in the United States, According
More informationTherapy of Hematologic Malignancies Period at high risk of IFI
Therapy of Hematologic Malignancies Period at high risk of IFI Neutrophils (/mm 3 ) 5 Chemotherapy Conditioning Regimen HSCT Engraftment GVHD + Immunosuppressive Treatment Cutaneous and mucositis : - Direct
More informationWhat have we learned about systemic antifungals currently available on the market?
2nd ECMM/CEMM Workshop Milano, September 25, 2010 What have we learned about systemic antifungals currently available on the market? Prof. Dr. Georg Maschmeyer Dept. of Hematology, Oncology & Palliative
More informationTop 5 papers in clinical mycology
Top 5 papers in clinical mycology Dirk Vogelaers Department of General Internal Medicine University Hospital Ghent Joint symposium BVIKM/BSIMC and SBMHA/BVMDM Influenza-associated aspergillosis in critically
More informationRezafungin: A Novel Echinocandin. Taylor Sandison, MD MPH Chief Medical Officer ISHAM- Amsterdam July 2, 2018
: A Novel Echinocandin Taylor Sandison, MD MPH Chief Medical Officer ISHAM- Amsterdam July 2, 2018 Disclosures Dr. Sandison is an employee of and stockholder in Cidara Therapeutics. Cidara Pipeline Program
More informationSolid organ transplant patients
M.6 Meet-the-expert sessions Solid organ transplant patients Martin Iversen, Denmark José M. Aguado, Spain Copenhagen, Sunday 13 October 2013 Conflict of interest disclosure In the past 5 years, J.M.A.
More informationAntifungals and current treatment guidelines in pediatrics and neonatology
Dragana Janic Antifungals and current treatment guidelines in pediatrics and neonatology Dragana Janic. University Children`s Hospital, Belgrade, Serbia 10/10/17 Hotel Crowne Plaza, Belgrade, Serbia; www.dtfd.org
More informationWhen is failure failure?
When is failure failure? Bart-Jan Kullberg, M.D. Radboud University Nijmegen The Netherlands The ICU patient with candidemia!! Female, 39 years old!! Multiple abdominal surgeries for Crohn's disease!!
More informationADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS
ADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS COMMERCIAL RELATIONS DISCLOSURE 2500 9000 15000 Astellas Gilead Sciences Pfizer Inc Expert advice Speaker s bureau Speaker s bureau OUTLINE OF THE PRESENTATION
More informationSCIENTIFIC DISCUSSION
London, 14 July 2004 Product name: Cancidas Procedure No. EMEA/H/C/379/II/17 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 68
More informationScottish Medicines Consortium
Scottish Medicines Consortium anidulafungin 100mg powder and solvent for concentrate for solution for infusion (Ecalta ) No. (465/08) Pfizer Ltd 09 May 2008 The Scottish Medicines Consortium (SMC) has
More informationAntifungal therapy in children. Adilia Warris MD PhD FRCPCH Clinical Reader Pediatric Infectious Diseases Specialist
Antifungal therapy in children Adilia Warris MD PhD FRCPCH Clinical Reader Pediatric Infectious Diseases Specialist Invasive fungal infections in Pediatrics Children and adolescents are similarly vulnerable
More informationAntifungal Therapy in Leukemia Patients
Antifungal Therapy in Leukemia Patients UPDATE ECIL 4, 6 September 2011 Raoul Herbrecht, Ursula Flückiger, Bertrand Gachot, Patricia Ribaud, Anne Thiebaut, Catherine Cordonnier UPDATE ECIL 4, 2011 UPDATE
More informationAntifungal Update 2/22/12. Which is the most appropriate initial empirical therapy in a candidemic patient?
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco 3/3 blood cultures are positive for an unidentified
More informationCURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS. Dr AMIT RAODEO DM SEMINAR
CURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS Dr AMIT RAODEO DM SEMINAR Introduction The incidence of invasive fungal infections in critically ill intensive
More informationTreatment and Prophylaxis
Treatment and Prophylaxis Andreas H. Groll, M.D. Infectious Disease Research Program Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology University Children s Hospital
More informationTOWARDS PRE-EMPTIVE? TRADITIONAL DIAGNOSIS. GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% β-d-glucan Neg Predict Value 100% PCR
TOWARDS PRE-EMPTIVE? GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% TRADITIONAL DIAGNOSIS β-d-glucan Neg Predict Value 100% PCR diagnostics FUNGAL BURDEN FIRST TEST POSITIVE FOR ASPERGILLOSIS
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 23 September 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 23 September 2009 CANCIDAS 50 mg, powder for concentrate for solution for infusion Vial containing 10 ml, B/1 (CIP:
More informationAntifungal Update. Candida: In Vitro Antifungal Susceptibility Testing
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco The patient spikes a new fever and 3/3 blood
More informationFK463 Protocol No /FG Report FG , July 29, I -
- I - SYNOPSIS Name of Sponsor/Company: Fujisawa GmbH Name of Finished Product: Not Yet Named Name of Active Ingredient: Micafungin, JPN (FK463) Title of Study: An Open-Label, Non-Comparative Study Of
More informationNationwide survey of treatment for pediatric patients with invasive fungal infections in Japan
J Infect Chemother (2013) 19:946 950 DOI 10.1007/s10156-013-0624-7 ORIGINAL ARTICLE Nationwide survey of treatment for pediatric patients with invasive fungal infections in Japan Masaaki Mori Received:
More informationOliver A. Cornely. Department I for Internal Medicine Haematology / Oncology / Infectious Diseases / Intensive Care 2. Centre for Clinical Research
Management of Confirmed Aspergillosis Oliver A. Cornely 1 Department I for Internal Medicine Haematology / Oncology / Infectious Diseases / Intensive Care 2 Centre for Clinical Research University of Cologne
More informationTRANSPARENCY COMMITTEE OPINION. 8 November 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 8 November 2006 VFEND 50 mg, film-coated tablets B/28 (CIP: 3592886) B/56 (CIP: 3592892) VFEND 200 mg, film-coated
More informationESCMID Online Lecture Library. by author
The antibacterial experience: indications for clinical use of antimicrobial combinations To prevent the emergence of resistant organisms (tuberculosis) To treat polymicrobial infections (abdominal complicated
More informationCase Studies in Fungal Infections and Antifungal Therapy
Case Studies in Fungal Infections and Antifungal Therapy Wayne L. Gold MD, FRCPC Annual Meeting of the Canadian Society of Internal Medicine November 4, 2017 Disclosures No financial disclosures or industry
More informationHow Can We Prevent Invasive Fungal Disease?
How Can We Prevent Invasive Fungal Disease? Chris Kibbler Professor of Medical Microbiology University College London And Royal Free Hospital, London, UK Invasive Aspergillosis 2 - Acquisition Preventive
More informationInvasive Fungal Infections in Solid Organ Transplant Recipients
Outlines Epidemiology Candidiasis Aspergillosis Invasive Fungal Infections in Solid Organ Transplant Recipients Hsin-Yun Sun, M.D. Division of Infectious Diseases Department of Internal Medicine National
More informationAntifungal Stewardship. Önder Ergönül, MD, MPH Koç University, School of Medicine, Istanbul 6 October 2017, ESGAP course, Istanbul
Antifungal Stewardship Önder Ergönül, MD, MPH Koç University, School of Medicine, Istanbul 6 October 2017, ESGAP course, Istanbul 1 2 Objectives What do we know? Invasive Candida and Aspergillosis Impact
More informationTitle: Author: Speciality / Division: Directorate:
Antifungal guidelines for CANDIDIASIS INFECTIONS (Adults) Proven infection: Targeted antifungal therapy should be prescribed for: o Positive cultures from a sterile site with clinical or radiological abnormality
More informationAntifungal Update 2/24/11. Which is the most appropriate initial empirical therapy in a candidemic patient?
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco The patient spikes a new fever and 3/3 blood
More informationFungal Infection in the ICU: Current Controversies
Fungal Infection in the ICU: Current Controversies Andrew F. Shorr, MD, MPH, FCCP, FACP Washington Hospital Center Georgetown University, Washington, DC Disclosures I have served as a consultant to, researcher/investigator
More informationAntifungal Pharmacodynamics A Strategy to Optimize Efficacy
Antifungal Pharmacodynamics A Strategy to Optimize Efficacy David Andes, MD Associate Professor, Department of Medicine Division of Infectious Diseases Medical Microbiology and Immunology University of
More informationWHAT IS THE ROLE OF EMPIRIC TREATMENT FOR SUSPECTED INVASIVE CANDIDIASIS IN NONNEUTROPENIC PATIENTS IN THE ICU?
WHAT IS THE ROLE OF EMPIRIC TREATMENT FOR SUSPECTED INVASIVE CANDIDIASIS IN NONNEUTROPENIC PATIENTS IN THE ICU? Empiric antifungal therapy should be considered in critically ill patients with risk factors
More informationItraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston
REVIEW Itraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston Division of Hematology-Oncology, Department of Medicine, UCLA Medical Center, Los
More informationFungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia
Fungal infections in ICU Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia Epidemiology of invasive fungal infections - US +300% Martin GS, et al. N Engl J Med 2003;348:1546-1554
More informationAntifungal Treatment in Neonates
Antifungal Treatment in Neonates Irja Lutsar University of Tartu, Estonia Lisbon, 12. October 2015 Prevalence of invasive fungal infections in NeoINN database 2005-2014 UK; 2012-2014 Estonia & Greece 1
More informationAntifungal Agents - Cresemba (isavuconazonium), Vfend. Prior Authorization Program Summary
Antifungal Agents - Cresemba (isavuconazonium), Noxafil (posaconazole), Vfend (voriconazole) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1,2,14 Drug FDA Indication(s) Dosing Cresemba
More informationWHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS?
WHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS? Assoc. Prof. Dr. Serkan SENER Acibadem University Medical School Department of Emergency Medicine, Istanbul Acibadem Ankara Hospital,
More informationPediatric greater than 30 kg. 2.5 mg/kg/day (maximum 150 mg daily)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use MYCAMINE safely and effectively. See full prescribing information for MYCAMINE. MYCAMINE (micafungin
More informationEvidence-Based Approaches to the Safe and Effective Management of Invasive Fungal Infections. Presenter. Disclosures
Evidence-Based Approaches to the Safe and Effective Management of Invasive Fungal Infections Presenter James S. Lewis II, PharmD, FIDSA ID Clinical Pharmacy Coordinator Oregon Health and Science University
More informationPROGRESSI NELLA TERAPIA ANTIFUNGINA. A tribute to Piero Martino
PROGRESSI NELLA TERAPIA ANTIFUNGINA A tribute to Piero Martino 1946-2007 ITALIAN ICONS IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI 1961 CAUSES OF DEATH IN PATIENTS WITH MALIGNANCIES
More informationLondon New Drugs Group APC/DTC Briefing
London New Drugs Group APC/DTC Briefing Posaconazole for invasive fungal infections Contents Background 2 Dosing Information 3 Clinical evidence for treatment of infections 3 Clinical evidence for prophyactic
More informationCD101: A Novel Echinocandin
CD101: A Novel Echinocandin Taylor Sandison, MD MPH Chief Medical Officer TIMM Belgrade, Serbia October 8, 2017 1 Disclosures Dr. Sandison is an employee of and stockholder in Cidara Therapeutics 2 Cidara
More informationEmpirical Antifungal Therapy 2009 Update of ECIL-1 / ECIL-2 Guidelines O. Marchetti, C. Cordonnier, T. Calandra
UPDATE ECIL-3 2009 Empirical Antifungal Therapy 2009 Update of ECIL-1 / ECIL-2 Guidelines O. Marchetti, C. Cordonnier, T. Calandra 1 Background Empirical antifungal therapy for suspected invasive fungal
More information9/7/2018. Faculty. Overcoming Challenges in the Management of Invasive Fungal Infections. Learning Objectives. Faculty Disclosure
Faculty Overcoming Challenges in the Management of Invasive Fungal James S. Lewis II, PharmD, FIDSA ID Clinical Pharmacy Coordinator Oregon Health and Science University Departments of Pharmacy and Infectious
More informationCondition First line Alternative Comments Candidemia Nonneutropenic adults
Recommendations for the treatment of candidiasis. Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America. Condition First line Alternative
More informationThe Hospital for Sick Children Technology Assessment at Sick Kids (TASK) EXECUTIVE SUMMARY
The Hospital for Sick Children Technology Assessment at Sick Kids (TASK) EXECUTIVE SUMMARY CASPOFUNGIN IN THE EMPIRIC TREATMENT OF FEBRILE NEUTROPENIA IN PEDIATRIC PATIENTS: A COMPARISON WITH CONVENTIONAL
More informationAn Update in the Management of Candidiasis
An Update in the Management of Candidiasis Daniel B. Chastain, Pharm.D., AAHIVP Infectious Diseases Pharmacy Specialist Phoebe Putney Memorial Hospital Adjunct Clinical Assistant Professor UGA College
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE. Opinion. 5 March 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 5 March 2008 ECALTA 100 mg, powder and solvent for concentrate for solution for infusion Box containing 1 30 ml glass
More informationHOW TO DEFINE RESPONSE IN ANTIFUNGAL CLINICAL TRIALS?
HOW TO DEFINE RESPONSE IN ANTIFUNGAL CLINICAL TRIALS? EORTC IFICG START Look for Help? MORTALITYASSOCIATED WITH INVASIVE ASPERGILLOSIS Lin et al. Clin Infect Dis 2001;32:358 100 % 50 n = 178 0 0 60 120
More informationAntifungal prophylaxis in haematology patients: the role of voriconazole
REVIEW 10.1111/j.1469-0691.2012.03772.x Antifungal prophylaxis in haematology patients: the role of voriconazole Y. Hicheri 1, G. Cook 2 and C. Cordonnier 1 1) Service d Hématologie Clinique, Assistance
More informationTrends in Invasive Fungal Infection (IFI) in Haematology-Oncology Patients. Saturday, April 18, 2015 Charlottetown, P.E.I.
Trends in Invasive Fungal Infection (IFI) in Haematology-Oncology Patients Saturday, April 18, 2015 Charlottetown, P.E.I. Moderator & Speaker: Shariq Haider MD, FRCPC, FACP, CCST(UK), DTMH(UK) Professor
More informationPediatric greater than 30 kg. 2 mg/kg/day (maximum 100 mg daily) 2.5 mg/kg/day (maximum 150 mg daily) 1 mg/kg/day (maximum 50 mg daily)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use MYCAMINE safely and effectively. See Full Prescribing Information for MYCAMINE. MYCAMINE (micafungin
More informationUpdate on Candida Infection Nov. 2010
Update on Candida Infection Nov. 2010 Gary Wong Pharmacy Clinical site leader University Health Network Course coordinator University of Toronto Goals What is an yeast infection Risk factors for yeast
More informationVoriconazole October 2015 Risk Management Plan. Voriconazole
Voriconazole October 2015 VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Invasive aspergillosis (IA) is the most devastating of Aspergillus related diseases, targeting severely
More information1. Pre-emptive therapy. colonization, colonization, pre-emptive therapy. , ICU colonization. colonization. 2, C. albicans
Jpn. J. Med. Mycol. Vol. 45, 217 221, 2004 ISSN 0916 4804,.,, colonization, pre-emptive therapy. 2, non-albicans Candida., fluconazole.,. Key words: postoperative infection, non-albicans Candida, pre-emptive
More informationIsavuconazole. Lepak et al 2013 Antimicrob Agents Chemother 57: Lepak et al 2013 Antimicrob Agents Chemother 57:
Priv.-Doz. Dr. med. Maria J.G.T. Vehreschild Department I of Internal Medicine Clinical Trials Unit II Infectious Diseases Research Group Clinical Microbiome Isavuconazole 09.07.2017 Maria J.G.T. Vehreschild
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Voriconazole Effective Date... 3/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 4004 Table of Contents Coverage Policy... 1 General Background...
More informationIs pre-emptive therapy a realistic approach?
Is pre-emptive therapy a realistic approach? J Peter Donnelly PhD, FRCPath Department of Haematology Radboud University Nijmegen Medical Centre Nijmegen, The Netherlands Is pre-emptive therapy a realistic
More informationCANCIDAS PRODUCT MONOGRAPH. Caspofungin for injection, 50 mg/vial, 70 mg/vial (as caspofungin actetate) Antifungal. Date of Revision: April 28, 2017
PRODUCT MONOGRAPH Caspofungin for injection, 50 mg/vial, 70 mg/vial (as caspofungin actetate) Antifungal Merck Canada Inc. 16750 route Transcanadienne Kirkland, QC Canada H9H 4M7 www.merck.ca Date of Revision:
More informationFungi GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Fungi Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA Chapter Editor Ziad A. Memish, MD, FRCPC, FACP Cover heading - Topic Outline Topic outline
More informationSTRIVE Part A Phase 2 topline data. March 2018
STRIVE Part A Phase 2 topline data March 2018 Cidara Pipeline Programs Indication Discovery Research/ in vitro in vivo IND Enabling Phase 1 Phase 2 Phase 3 Treatment (Candida) Infectious Disease Focus
More informationNew Directions in Invasive Fungal Disease: Therapeutic Considerations
New Directions in Invasive Fungal Disease: Therapeutic Considerations Coleman Rotstein, MD, FRCPC, FACP University of Toronto University Health Network Toronto, Ontario Disclosure Statement for Coleman
More informationColeophoma empetri FR901379, Fig. 1, ,,, 1,3- -D-glucan. . C. albicans A. fumigatus. Dixon plot C. albicans A. fumigatus 1,3- -D-glucan
Jpn. J. Med. Mycol. Vol. 46, 217222, 2005 ISSN 09164804,,,. echinocandin, pneumocandin. FR901379,., 1,3--D-glucan,,,., in vitro.,.,,. 2002,., 3,. Key words: micafungin, echinocandin, 1,3--D- 1,3--D-glucan
More informationPRODUCT MONOGRAPH. Caspofungin for Injection. 50 mg/vial, 70 mg/vial. Caspofungin (as caspofungin acetate) Antifungal
PRODUCT MONOGRAPH Pr. Caspofungin for Injection 50 mg/vial, 70 mg/vial Caspofungin (as caspofungin acetate) Antifungal MDA inc. 206-2401 Bristol Circle Oakville, ON L6H 5S9 Date of Preparation: January
More informationConsiderations for Antifungal Management in Pediatric Cancer Patients
Considerations for Antifungal Management in Pediatric Cancer Patients Andreas H. Groll, M.D. Infectious Disease Research Program Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology
More informationOptimizing antifungal dosing regimens. Joseph Meletiadis, PhD, FECMM Assistant Professor of Microbiology
ATHENA 2017 International Conference November 28 30, 2017 Optimizing antifungal dosing regimens Joseph Meletiadis, PhD, FECMM Assistant Professor of Microbiology Clinical Microbiology Laboratory, «Attikon»
More informationPediatric Master Protocols
Pediatric Master Protocols Overall Assessment and Pathway Forward Friday, September 23, 2016 Mycamine (micafungin sodium) Member of the echinocandin class of antifungals Approved in the U.S. for adults
More informationLiposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients
ORIGINAL ARTICLE MYCOLOGY Liposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients K. Bochennek 1, L. Tramsen 1, N. Schedler 1, M. Becker 1, T. Klingebiel
More informationUse of Antifungal Drugs in the Year 2006"
Use of Antifungal Drugs in the Year 2006" Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine
More informationOutline NEW DIAGNOSTIC TOOLS WHY? WHICH TESTS? WHEN TO USE THEM? Documented IFI
New Developments and Challenges in Diagnostics of Invasive Fungal Infections O. Marchetti, MD Infectious Diseases Service, Department of Medicine, CHUV and University of Lausanne, Switzerland Workshop
More informationApproach to the Transplant Patient. Amy Musiek, MD AAD Annual Meeting 2018
Approach to the Transplant Patient Amy Musiek, MD AAD Annual Meeting 2018 Disclosures Actelion: speaker, advisory board, investigator Elorac: investigator Kyowa: investigator, advisory board Seattle genetics:
More informationFor the use only of a Registered Medical Practitioner or a Hospital or a Laboratory
For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory MYCAMINE 50 mg / 100 mg Micafungin Sodium for Injection 50 mg / 100 mg QUALITATIVE AND QUANTITATIVE COMPOSITION Mycamine
More informationGemcitabine + Capecitabine (ESPAC-4 Trial)
Gemcitabine + Capecitabine (ESPAC-4 Trial) European Study Group For Pancreatic Cancer - Trial 4. Combination versus single agent chemotherapy in resectable pancreatic ductal and ampullary cancers. ***
More informationProphylaxis, Empirical, Pre-emptive Therapy of Aspergillosis in Hematological Patients: Which Strategy?
TIMM-4 18-21 October 2009 Athens, Greece Prophylaxis, Empirical, Pre-emptive Therapy of Aspergillosis in Hematological Patients: Which Strategy? www.ichs.org Georg Maschmeyer Dept. of Hematology, Oncology
More informationAntifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences
5th MMTN Conference 5-6 November 2016 Bangkok, Thailand 10:20-10:45, 6 Nov, 2016 Antifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences Yee-Chun Chen, M.D., PhD. Department of Medicine,
More informationProphylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases. Y.L. Kwong Department of Medicine University of Hong Kong
Prophylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases Y.L. Kwong Department of Medicine University of Hong Kong Pathogenic yeast Candida Cryptococcus Trichosporon Pathogenic
More informationSystemic Candidiasis for the clinicians: between guidelines and daily clinical practice
Systemic Candidiasis for the clinicians: between guidelines and daily clinical practice Anastasia Antoniadou Assoc. Professor Internal Medicine and Infectious Diseases National and Kapodistrian University
More informationVoriconazole Rationale for the EUCAST clinical breakpoints, version March 2010
Voriconazole Rationale for the EUCAST clinical breakpoints, version 2.0 20 March 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationVoriconazole in Prevention and Treatment of Febrile Neutropenia
2016 jpc.tums.ac.ir Voriconazole in Prevention and Treatment of Febrile Neutropenia Hamidreza Taghva Masoumi 1, Molouk Hadjibabaie 1,2, Kheirollah Gholami 1,2, Maryam Shahrokhi 1* 1 Clinical Pharmacy Department,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs.
More informationEMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS
EMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS DR LOW CHIAN YONG MBBS, MRCP(UK), MMed(Int Med), FAMS Consultant, Dept of Infectious Diseases, SGH Introduction The incidence of invasive fungal
More informationNEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATIONS. 20th Symposium (spring 2003) Thursday May 22nd 2003
NEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATINS 20th Symposium (spring 2003) Thursday May 22nd 2003 The slides presented at this meeting are available on this site as "Web slide shows" and
More informationSafety and Efficacy of Intermittent Intravenous Administration of High-Dose Micafungin
SUPPLEMENT ARTICLE Safety and Efficacy of Intermittent Intravenous Administration of High-Dose Micafungin Dionysis Neofytos, 1,a,b Yao-Ting Huang, 1,a Kimberly Cheng, 1 Nina Cohen, 1 Miguel-Angel Perales,
More informationRecent advances in the treatment of IFIs Newer antifungals: what s in the pipeline
Recent advances in the treatment of IFIs Newer antifungals: what s in the pipeline George Petrikkos, MD, Professor of Internal Medicine and Infectious Diseases National and Kapodistrian University of Athens
More informationOptimal Management of Invasive Aspergillosis in the Context of New Guidelines in High Risk Haematological Patients
Optimal Management of Invasive Aspergillosis in the Context of New Guidelines in High Risk Haematological Patients Shariq Haider Professor Medicine McMaster University Conflict of Interest Disclosure Slide
More informationPrimary prophylaxis of invasive fungal infection in patients with haematological diseases
Primary prophylaxis of invasive fungal infection in patients with haematological diseases Tunis, May 24 2012 Important questions for antifungal prophylaxis Who are the patients at risk? Which is the risk:
More informationNew Options for Prevention & Treatment of Invasive Fungal Infections
New Options for Prevention & Treatment of Invasive Fungal Infections Taylor Sandison, MD, MPH Chief Medical Officer Cidara Therapeutics, Inc. HTIDE 2018, Venice Cidara Pipeline Program Indication Discovery
More informationINFEZIONI FUNGINE E PERCORSI TERAPEUTICI IN ICU. Claudio Viscoli Professor of Infectious Disease University of Genoa
INFEZIONI FUNGINE E PERCORSI TERAPEUTICI IN ICU Claudio Viscoli Professor of Infectious Disease University of Genoa What I would like to discuss with you today When to start an antifungal therapy (before
More informationNo Evidence As Yet. Georg Maschmeyer. Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam, Germany
Is Combined Antifungal Therapy More Efficient than Single Agent Therapy? No Evidence As Yet www.ichs.org Georg Maschmeyer Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam,
More informationTreatment Guidelines for Invasive Aspergillosis
Treatment Guidelines for Invasive Aspergillosis Thomas F. Patterson, MD Professor of Medicine Director, San Antonio Center for Medical Mycology The University of Texas Health Science Center at San Antonio
More informationVoriconazole 200 mg powder for solution for infusion 03 Jun version 3.0 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN
Voriconazole 200 mg powder for solution for infusion 03 Jun. 2015 version 3.0 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Voriconazole
More informationSafety and tolerability of caspofungin acetate in the treatment of fungal infections
C.A. Sable B-Y T. Nguyen J.A. Chodakewitz M.J. DiNubile Safety and tolerability of caspofungin acetate in the treatment of fungal infections Key words: caspofungin; echinocandin; esophageal candiasis;
More informationESCMID Online Lecture Library. by author. Salvage Therapy of Invasive Aspergillosis Refractory to Primary Treatment with Voriconazole
Salvage Therapy of Invasive Aspergillosis Refractory to Primary Treatment with Voriconazole J.A. Maertens, hematologist, MD, PhD University Hospital Gasthuisberg Leuven, Belgium Current guidelines: first-line
More information